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Abstract. Cirrhosis is the dominant cause of portal hypertension globally butmaybe overshadowedby hepatosplenic
schistosomiasis (HSS) in the tropics. In Zambia, schistosomiasis seroprevalence can reach 88% in endemic areas.
Bacterial translocation (BT) drives portal hypertension in cirrhosis contributing to mortality but remains unexplored in
HSS. Rifaximin, a non-absorbable antibiotic may reduce BT. We aimed to explore the inﬂuence of rifaximin on BT,
inﬂammation, and ﬁbrosis in HSS. In this phase II open-label trial (ISRCTN67590499), 186 patients with HSS in Zambia
were evaluated and 85 were randomized to standard care with or without rifaximin for 42 days. Changes in markers of
inﬂammation, BT, and ﬁbrosis were the primary outcomes. BTwasmeasured using plasma 16S rRNA, lipopolysaccharide-
binding protein, and lipopolysaccharide, whereas hyaluronan was used to measure ﬁbrosis. Tumor necrosis factor
receptor 1 (TNFR1) and soluble cluster of differentiation 14 (sCD14) assessed inﬂammation. 16S rRNA reduced from
baseline (median146 copies/μL, interquartile range [IQR] 9, 537) to day42 in the rifaximingroup (median63 copies/μL, IQR12,
196),P < 0.01. The rise in sCD14 was lower (P < 0.01) in the rifaximin group (median rise 122 ng/mL, IQR-184, 783) than in
the non-rifaximin group (median rise 832 ng/mL, IQR530, 967). TNFR1decreased (P< 0.01) in the rifaximin group (median
-39 ng/mL IQR-306, 563) but increased in the non-rifaximin group (median 166 ng/mL, IQR 3, 337). Other markers
remained unaffected. Rifaximin led to a reduction of inﬂammatory markers and bacterial 16S rRNA which may im-
plicate BT in the inﬂammation in HSS.
INTRODUCTION
The most signiﬁcant cause of mortality and morbidity in
patients with hepatosplenic schistosomiasis (HSS) is variceal
bleeding as a result of portal hypertension.1–3 The commonest
cause of portal hypertension globally is cirrhosis but in the
tropics, HSS dominates.4,5 In Zambia, the prevalence of
schistosomiasis can reach 77% in endemic parts of the
country,6 whereas in thewestern part of the country, Mutengo
et al. found active infection of 42% of adults screened and
Payne et al. found seroprevalence to be 88% in the same
district.7,8
Bacterial translocation (BT) in cirrhosis contributes to portal
hypertension and is themain cause ofmortality.9 BT is deﬁned
as the movement of bacteria from the intestine to the mes-
enteric lymph nodes and/or portal vein then into the systemic
circulation.10–14 In cirrhosis, endotoxins and other vasoactive
mediators, because of BT, cause a vasodilatory effect and
increases splanchnic blood ﬂow which in turn leads to in-
creased portal hypertension15 and may precipitate variceal
hemorrhage. Others have speculated that endotoxins result in
release of endothelin-1 after cytokine activation. Endothelin-1
then leads to increased portal pressure by increasing vascular
resistance.16,17 Use of antibiotics in managing spontaneous
bacterial peritonitis (SBP) in cirrhosis iswidely advocated.13–15
We know that SBP occurs because of BT in cirrhosis18 but it is
unclear if SBP occurs in HSS.
BT remains unexplored in HSS and we are not sure whether
it contributes to portal hypertension in these patients. A short
report from Western Kenya suggested that there is increased
endotoxaemia in patients exposed to Schistosomamansoni,19
but it was not established if patients had portal hypertension.
Another study suggested that BT may play a role in post-
operative infectious complications in patients with schisto-
somal portal hypertension.20 In a case–control study, we
recently demonstrated that HSS is characterized by in-
ﬂammatory cytokines that may be as a result of BT from the
gut.2 Proof of causation is difﬁcult to secure, so we attempted
to conﬁrm the occurrence of BT in HSS by giving rifaximin
orally to reduce gut microbial contents. Rifaximin is a broad-
spectrum antibiotic and is active against gram-negative and
gram-positive bacteria including anaerobes and is minimally
absorbable.18,21 Therefore, effects of downstream patho-
physiology would implicate BT. We postulated that if the
markers of BTduring treatmentwith rifaximin are reduced, this
would be strong evidence that bacteria are translocating from
the gut and driving inﬂammation.
We therefore set out to investigate if giving rifaximin to pa-
tients with HSS would reduce the markers of BT and conse-
quently reduce the systemic inﬂammatory markers. We also
explored the effect of rifaximin on hyaluronan (HA), a ﬁbrotic
marker in these patients.
MATERIALS AND METHODS
Study design. This was a phase II open-label randomized
control trial, but all primary endpoints were measured in the
laboratory by staff members who were unaware of the treat-
ment allocation. Consent from the patients was obtained in
writing and verbally. Randomization was carried out using a
list of codes prepared by an independent advisor with a ran-
dom number generator. Sequential patients were enrolled
and their treatment allocation was decided by referring to the
code list.
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Study population. Patients were recruited in the De-
partment of Internal Medicine and Endoscopy Unit of the Uni-
versity Teaching Hospital, Lusaka, Zambia, between January
2014 and August 2016. Inclusion criteria were hematemesis
and/or splenomegaly, varices,18yearsandabove, andpositive
serology for schistosomiasis. Exclusion criteria were cirrhosis,
seropositive for human immunodeﬁciency virus, hepatitis B
virus, hepatitis C virus, or inability to give consent.
Studymedication.Of the186patientswhowere evaluated,
85patients fulﬁlled thecriteria andwere randomized to rifaximin
600 mg orally twice per day with standard care, or standard
care only, and followed up for 42 days. Standard care for
both groups comprised praziquantel 40 mg per kg body
weight givenorally in divideddosesover 1dayandpropranolol
40 mg three times per day, escalating the dosage upward
as tolerated and aiming for reduction in resting pulse rate to
below 60 beats/minute. Drugs were self-administered orally
at home. Adherence to rifaximin wasmonitored by self-report.
Evaluation criteria. All patients were to complete a 42-day
follow-up. The primary outcomes in this study were changes in
plasma inﬂammatory, BT, and ﬁbrotic markers over a 42-day
period of rifaximin. The secondary outcomes were response to
beta blockers, variceal rebleeding episodes, and mortality.
Safetywasassessedbyadverseeventsand the laboratory tests.
Assessments. A questionnaire was administered at base-
line and at the end of the follow-up period. The questionnaire
captured demographic data including history of contact with
water bodies. Medical history in the questionnaire included
hematemesis, abdominal pain, abdominal swelling, yellowing
of eyes, fever, andnumber of tablets of rifaximinmissedduring
the clinical trial. Physical examination was done at baseline
and at day 42 and this information was recorded in the
questionnaire. Examination included all systems with much
emphasis on the liver and the gastrointestinal system. The
information in the questionnaire was useful in analyzing vari-
ous outcomes of the clinical trial.
Ten milliliters of blood was drawn from each patient at
baseline and day 42 and collected in tubes containing heparin
FIGURE 1. Trial ﬂowchart.
TABLE 1
Baseline demographic and clinical data, inﬂammatory, translocation,
and other blood markers
Variable Rifaximin group Non-rifaximin group
Age (years) 42 (30, 52) 38 (31,43)
Gender Females 24 Females 16
Males 20 Males 25
BMI (kg/m2) 21.6 (19.9, 23.2) 21.5 (20.3, 23.8)
No. of cases
with
history of
hematemesis
Yes 27 Yes 26
No 17 No 15
Pulse rate
(beats/minute)
76 (66, 82) 70 (64, 76)
Hb (g/dL) 7.5 (6.2, 11.3) 9.2 (6.6, 11.0)
WCC (×109/L) 2.7 (1.6, 3.5) 1.8 (1.6, 3.0)
PLT (×109/L) 49 (31, 78) 44 (24, 64)
MCV (ﬂ) 80 (67, 87) 79 (70, 83)
MPV (mm) 12.7 (11.2, 13.9) 12.1 (10.8, 13.6)
16S rRNA
copies/μL
129 (23, 499) 51 (19, 112)
LPS (ng/mL) 74 (38, 157) 154 (45, 649)
LBP (ng/mL) 27 (23, 30) 43 (38, 50)
TNFR1 (ng/mL) 1,443 (1,232,1,911) 1,495 (1,238,1,657)
sCD14 (ng/mL) 2,402 (1,930,2,798) 1,487 (1,299,1,964)
Hyaluronan
(ng/mL)
125 (57, 189) 102 (71, 176)
BMI = body mass index; Hb = hemoglobin; LBP = lipopolysaccharide-binding protein;
LPS = lipopolysaccharide; MCV =mean cell volume; MPV =main portal vein diameter; PLT =
platelets; sCD14 = soluble cluster of differentiation 14; WCC = white cell count; TNFR1 =
tumor necrosis factor receptor 1.
All parameters are represented as median with interquartile range in parenthesis.
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anticoagulant. Full blood count wasmeasured using a Sysmex
800i analyzer, Kobe, Japan. The rest of the blood sample was
centrifuged at 3,000 rpmat 4C for 5minutes. The plasmawas
aliquoted into triplicates and stored at −80C. The inﬂam-
matory markers measured were tumor necrosis factor
receptor 1 (TNFR1) and soluble cluster of differentiation
14 (sCD14). To measure BT, 16S rRNA, lipopolysaccharide
(LPS), and lipopolysaccharide-binding protein (LBP) were
used, whereas HA was used to measure ﬁbrosis.2 Limulus
amoebocyte lysate chromowas used to detect LPS in plasma
(Associates of Cape Cod Incorporated, Falmouth, MA). DNA
was extracted using plasma Qiagen DNA extraction kit
according to the manufacturer’s instructions. Quantitative
polymerase chain reaction was used to quantify DNA of the
16S rRNAgeneas an indication forBT. LBPwasalsousedasa
biomarker of BT,2 using enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Abingdon, United Kingdom) at 2-fold
dilution. HAwasmeasured byELISA (R&DSystems) at 80-fold
dilution.
TNFR1 was used as a measure of tumor necrosis factor
alpha activity in blood22 using ELISA (R&DSystems) at 10-fold
dilution. sCD14was also determined by ELISA (R&DSystems)
at 400-fold dilution. ELISA assays were run in duplicate with
appropriate controls and analyzed on a Biotek EL 800 ELISA
plate reader using Gen5 1.10 software.
Statistical analysis. Assuming 95% conﬁdence interval,
with a reduction in BT in HSS, a sample size of 40 patients in
each group was sufﬁcient with power of 80% to detect a
signiﬁcant difference.
Data were entered into Microsoft Excel and imported to
STATA version 13.1 (Stata Corp, College Station, TX) and
GRAPHPAD PRISM 6.01 (GraphPad Software, San Diego,
CA) for analysis. Intention to treat analysis was used. For de-
scription purposes, we used median with interquartile range
because most of these data were not normally distributed. To
compare the blood tests between the groups, we used the
Mann–Whitney test for unpaired data. To compare measure-
ments from baseline to day 42 within the group, we used
Wilcoxon matched-pairs signed-rank test. A P value of less
that 0.05 was considered signiﬁcant.
Ethical approval. This study was approved by the Univer-
sity of Zambia Biomedical Research Ethics Committee (ref:
006-07-12) and Zambia Medicine Regulatory Board (clini-
cal trial number: CT046/13). The trial was registered interna-
tionally (ISRCTN67590499).
RESULTS
One hundred and eighty-six patients were evaluated and of
the 101 ineligible patients, most of themwere seronegative for
schistosomiasis (Figure 1); although many of these may have
had schistosomiasis in the past, we required seropositivity
to ensure homogeneity of the trial population. The rifaximin
and non-rifaximin groups were similar with respect to demo-
graphic and most laboratory data (Table 1). The commonest
cause of referral to the hospital was hematemesis (Table 1). At
baseline, most of the patients had pancytopenia, but there
was an increase in hemoglobin in both groups after 42 days of
follow-up; other full blood count indices remained the same
(Tables 1 and 2). There were apparent good responses to beta
blockade in both rifaximin and non-rifaximin groups after the
42-day follow-up (Table 2). Ten (23%) patients in rifaximin
groupand seven (24%)patients in the non-rifaximin grouphad
ascites at baseline. Even after 42 days of follow-up, eight
patients had ascites on physical examination, ﬁve (12%)
patients in the rifaximin group, and three (8%) patients in the
non-rifaximin group.All patients hadnormal body temperature
at baseline and after 42 days in both groups.
Primary efﬁcacy endpoints. There was reduction of 16S
rRNA, a marker of BT, sCD14, and TNFR1, inﬂammatory
markers for 42 days of rifaximin as shown in Figures 2 and 3.
There were no signiﬁcant changes in the plasma concentra-
tions of LPS, LBP, and HA after 42 days of rifaximin treatment
(Figures 4–6).
Secondary endpoints. There was good clinical effect of
beta blockade (reduction in resting pulse pressure). No patient
reported any episode of hematemesis.
Safety. There were no major adverse events reported dur-
ing a 42-day follow-up. One patient in the rifaximin group
TABLE 2
Assessment of pulse and full blood count at baseline and day 42
Variable Rifaximin group baseline Rifaximin group day 42 P value Non-rifaximin group baseline Non-rifaximin group day 42 P
Pulse rate (beats/minute) 76 (66, 82) 65 (60, 72) < 0.01 70 (64, 76) 66 (62, 70) 0.07
Hb (g/dL) 7.5 (6.2, 11.3) 11.5 (9.0,13.0) 0.01 9.2 (6.6, 11.0) 10.3 (8.5, 12.4) 0.03
MCV (ﬂ) 80 (67, 87) 76 (66, 86) 0.09 79.0 (70.2, 82.7 79.4 (68.1, 91.9) 0.82
WCC (×109/L) 2.7 (1.6, 3.5) 2.0 (1.6, 2.5) 0.04 1.8 (1.6, 3.0) 2.2 (1.6, 3.5) 0.67
RBC (×1012/L) 3.4 (2.7, 4.3) 4.5 (4.0, 4.9) 0.01 3.6 (3.0, 4.4) 4.3 (3.6, 5.2) 0.06
PLT (×109/L) 49 (31, 78) 42 (28, 72) 0.61 44 (24, 64) 38 (25, 52) 0.74
Hb = hemoglobin; MCV = mean cell volume; PLT = platelets; RBC = red blood cells; WCC = white cell count.
All parameters are represented as median with interquartile range in parenthesis.
FIGURE 2. Rifaximin led to the reduction of 16S rRNA copies/μL
over 42 days.
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reported an episode of rectal bleeding that required no in-
tervention. Another patient in the rifaximin group complained
of abdominal discomfort a week after starting taking rifaximin,
but this resolved without any intervention.
DISCUSSION
The reduction in inﬂammatory markers and 16S rRNA
copies after 42daysof intestinal decontaminationwith rifaximin
provide evidence that BT may have a clinical association with
inﬂammatory processes in HSS-related portal hypertension.
We know that BT is associated with cirrhosis, and this drives
the disease process by increasing portal hypertension.10,11
Our results suggest that similar mechanisms may also be
driving portal hypertension in HSS.
The pronounced reduction of systemic inﬂammatory
markers and the signiﬁcant reduction of 16S rRNA copies
might be explained by the contribution of BT as rifaximin is a
nonabsorbable oral antibiotic.18,23–27 The minimal reduction
of LPS is not inconsistent with this interpretation as LPS is a
constituent of gram-negative bacteria only,28 and it might be
expected that rifaximin would have a greater effect on gram-
positive bacterial loads. Among the inﬂammatorymarkers that
were reduced after 42 days of rifaximin treatment, sCD14 is
the marker which other researchers have associated with
BT.24,29–32 LPS elicits secretion of sCD14 from macrophages
including Kupffer cells after binding of LPS to toll-like receptor
4 in the presence of LBP and sCD14.24,25 For this reason,
activation of any of these markers could reﬂect BT. TNFR1,
another inﬂammatorymarker, also fell after 42daysof rifaximin
treatment which is consistent with BT as a driver of systemic
inﬂammation. Tarrats et al.33 haveassociatedTNFR1with liver
ﬁbrosis in animal models. LBP did not change much after
42 days of rifaximin in this clinical trial, which is somewhat at
odds with the effect we saw in the case–control study.2 Other
researchers have shown that LBP may also be elevated in
gram-positive sepsis in the elderly and those who are
obese.34–36 In this clinical trial, no patient had obesity and
therewas no extremity of age. The lack of effect of rifaximin on
LBPmayhave a similar explanation to that for the lack of effect
on LPS.
The only ﬁbrotic marker measured in patients in the clinical
trial was HAwhich was not affected by rifaximin. We think that
the duration of rifaximin was too short to have any impact on
HA, and by the time these patients present to hospital with
variceal bleeding ﬁbrosis is well established and likely to be
irreversible. HA is an important molecule which is associated
with hepatic ﬁbrosis in HSS.2,37 In an animal model of cirrho-
sis, ﬁbronectin, another ﬁbrotic marker, reduced after in-
testinal decontamination with rifaximin.38 It is not clear
whether this could translate to humans but our data suggest
not in the short term.
The pancytopenia in our patients is consistent with
hypersplenism. There was profound thrombocytopenia in
both groups but patients did not present with bleeding
during follow-up although Arthur and others have described
platelet counts of 100 × 109/L or less as being associated
with upper digestive bleeding even in asymptomatic HSS
patients.39
There were nomajor adverse events associatedwith rifaximin
during the 42-day follow-up period which is in agreement
with what others have said about the safety of rifaximin.18
The reason for the low variceal rebleeding rate during the
FIGURE 3. (A and B) Soluble CD14 (sCD14) and tumor necrosis
factor receptor 1 (TNFR1) plasma concentrations fell in the rifaximin
group over 42 days.
FIGURE 4. There was no signiﬁcant change in lipopolysaccharide (LPS) concentrations in either group over 42 days.
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42-day follow-up could be due to adherence to proprano-
lol as conﬁrmed by good beta blockade at the end of
42-day period in both groups compared with baseline. This
probably reﬂects the importance of beta blockers in pre-
venting variceal bleeding in schistosoma-related portal
hypertension.40
It is a limitation of this study that it was an open-label
clinical trial, which is prone to bias, although the laboratory
personnel were blinded. Conﬁrmation of compliance to
rifaximin in these patientswas not possible as rifaximin blood
levels could not be measured. The effect of BT on clinical
endpoints may also have been underestimated in this clinical
trial because the patients were stable and seen as outpa-
tients. Theydid not have acute variceal bleeds on recruitment
and would be predicted to have lower rebleeding rates on
follow-up.
CONCLUSION
We showed that rifaximin led to the reduction of systemic
inﬂammatory cytokines and bacterial 16S rRNA, a direct
marker of BT. This suggests that BT may be involved in the
pathophysiology of HSS and warrants the further study to
demonstrate if rifaximin gives clinical beneﬁt. It would be of
interest to study patients recruited immediately after acute
variceal bleeds, with clinical endpoints, perhaps as a multi-
center placebo-controlled trial on a larger scale.
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